Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples

References

• Stephan C, Jung K, Ralla B. Current biomarkers for diagnosing of prostate cancer. Future Oncol. 2015;11(20):2743–2755. doi:10.2217/fon.15.20326358139
   PubMed Web of Science ®Google Scholar
• Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449–455. doi:10.7326/M16-258628869989
   PubMed Web of Science ®Google Scholar
• Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K. Prostate-specific antigen (PSA) screening and new biomarkers for prostate cancer (PCa). EJIFCC. 2014;25(1):55.27683457
   PubMedGoogle Scholar
• Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol. 1999;162(2):293–306. doi:10.1016/S0022-5347(05)68543-610411025
   PubMed Web of Science ®Google Scholar
• Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16(2):95–101. doi:10.3122/jabfm.16.2.9512665174
   PubMedGoogle Scholar
• Ross T, Ahmed K, Raison N, Challacombe B, Dasgupta P. Clarifying the PSA grey zone: the management of patients with a borderline PSA. Int J Clin Pract. 2016;70(11):950–959. doi:10.1111/ijcp.1288327672001
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–916. doi:10.1056/NEJM1987100831715012442609
   PubMed Web of Science ®Google Scholar
• Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr. 2012;2012(45):146–151. doi:10.1093/jncimonographs/lgs03123271765
   PubMedGoogle Scholar
• Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–1055. doi:10.1016/j.eururo.2013.12.06224439788
   PubMed Web of Science ®Google Scholar
• Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193(4):1163–1169. doi:10.1016/j.juro.2014.10.12125463993
   PubMed Web of Science ®Google Scholar
• Valerio M, Donaldson I, Emberton M, et al. Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol. 2015;68(1):8–19. doi:10.1016/j.eururo.2014.10.02625454618
   PubMed Web of Science ®Google Scholar
• Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–1777. doi:10.1056/NEJMoa180199329552975
   PubMed Web of Science ®Google Scholar
• Kayano PP, Carneiro A, Castilho TML, et al. Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. Int Braz J Urol. 2018;44(6):1106–1113. doi:10.1590/s1677-5538.ibju.2017.055230325600
   PubMed Web of Science ®Google Scholar
• Li Q, Lu H, Choi J, et al. Radiological semantics discriminate clinically significant grade prostate cancer. Cancer Imaging. 2019;19(1):81. doi:10.1186/s40644-019-0272-y31796094
   PubMed Web of Science ®Google Scholar
• Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM. Should Gleason 6 be labeled as cancer? Curr Opin Urol. 2015;25(3):238–245. doi:10.1097/MOU.000000000000016525730327
   PubMed Web of Science ®Google Scholar
• Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368–374. doi:10.1001/jama.1994.035102900500367506797
   PubMed Web of Science ®Google Scholar
• Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw. 2018;16(5S):620–623. doi:10.6004/jnccn.2018.003629784740
   PubMed Web of Science ®Google Scholar
• Loeb S, Partin AW. Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. Rev Urol. 2011;13(4):e191.22232568
   PubMedGoogle Scholar
• Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69(3):532–535. doi:10.1016/j.urology.2006.12.01417382159
   PubMed Web of Science ®Google Scholar
• Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim Biophys Acta. 2014;1846(1):99–112. doi:10.1016/j.bbcan.2014.04.00124727384
   PubMed Web of Science ®Google Scholar
• Ali A, Hoyle A, Baena E, Clarke NW. Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis. Curr Opin Urol. 2017;27(3):217–224. doi:10.1097/MOU.000000000000038528212121
   PubMed Web of Science ®Google Scholar
• Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179(4):1587–1592. doi:10.1016/j.juro.2007.11.03818295257
   PubMed Web of Science ®Google Scholar
• Kanyong P, Rawlinson S, Davis J. Immunochemical assays and nucleic-acid detection techniques for clinical diagnosis of prostate cancer. J Cancer. 2016;7(5):523–531. doi:10.7150/jca.1382126958088
   PubMed Web of Science ®Google Scholar
• Rogers CG, Yan G, Zha S, et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol. 2004;172(4 Pt 1):1501–1503. doi:10.1097/01.ju.0000137659.53129.1415371879
   PubMed Web of Science ®Google Scholar
• Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD, Ho SM. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme A racemase in prostatic secretions. J Urol. 2004;172(3):1130–1133. doi:10.1097/01.ju.0000133560.87118.4d15311056
   PubMed Web of Science ®Google Scholar
• Zehentner BK, Secrist H, Zhang X, et al. Detection of α-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. Mol Diagn Ther. 2006;10(6):397–403. doi:10.1007/BF0325621717154657
   PubMed Web of Science ®Google Scholar
• Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of α-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol. 2009;181(6):2508–2514. doi:10.1016/j.juro.2009.01.11019371911
   PubMed Web of Science ®Google Scholar
• Ankerst DP, Hoefler J, Bock S, et al. The prostate cancer prevention trial risk calculator 2.0 for the prediction of low- versus high-grade prostate cancer. Urology. 2014;83(6):1362–1368. doi:10.1016/j.urology.2014.02.03524862395
   PubMed Web of Science ®Google Scholar
• Grill S, Fallah M, Leach RJ, et al. Incorporation of detailed family history from the Swedish family-cancer database into the prostate cancer prevention trial risk calculator. J Urol. 2014;193(2):460–465. doi:10.1016/j.juro.2014.09.01825242395
   PubMed Web of Science ®Google Scholar
• Marx A, Backes C, Meese E, Lenhof HP, Keller A. EDISON-WMW: exact dynamic programing solution of the Wilcoxon–Mann–Whitney test. Genomics Proteomics Bioinformatics. 2016;14(1):55–61. doi:10.1016/j.gpb.2015.11.00426829645
   PubMed Web of Science ®Google Scholar
• Goksuluk D, Korkmaz S, Zararsiz G, Karaagaoglu AE. EasyROC: an interactive web-tool for ROC curve analysis using R language environment. R J. 2016;8(2):213–230. doi:10.32614/RJ-2016-042
   Google Scholar
• Heidegger I, Skradski V, Steiner E, et al. High risk of under-grading and-staging in prostate cancer patients eligible for active surveillance. PLoS One. 2015;10(2):e0115537. doi:10.1371/journal.pone.011553725658878
   PubMed Web of Science ®Google Scholar
• Arias-Stella JA, Shah AB, Montoya-Cerrillo D, Williamson SR, Gupta NS. Prostate biopsy and radical prostatectomy gleason score correlation in heterogenous tumors. Am J Surg Pathol. 2015;39(9):1213–1218. doi:10.1097/PAS.000000000000049926274028
   PubMed Web of Science ®Google Scholar
• Meng FJ, Shan A, Jin L, Young CY. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev. 2002;11(3):305–309.11895882
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Levanon EY. Human housekeeping genes, revisited. Trends Genet. 2013;29(10):569–574. doi:10.1016/j.tig.2013.05.01023810203
   PubMed Web of Science ®Google Scholar
• Cui Y, Cao W, Li Q, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:25776. doi:10.1038/srep2577627161545
   PubMed Web of Science ®Google Scholar
• Haese A, de la Taille A, Van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54(5):1081–1088. doi:10.1016/j.eururo.2008.06.07118602209
   PubMed Web of Science ®Google Scholar
• de la Taille A, Irani J, Graefen M, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185(6):2119–2125. doi:10.1016/j.juro.2011.01.07521496856
   PubMed Web of Science ®Google Scholar
• Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico‐pathological characteristics of prostate cancer. Prostate. 2010;70(1):10–16. doi:10.1002/pros.2103219708043
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.126041925613900
   PubMed Web of Science ®Google Scholar
• Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(18):1914–1931. doi:10.1001/jama.2018.371229801018
   PubMed Web of Science ®Google Scholar